growth earli rais signal tavr expans may
larger durabl may chip away
strong quarter tavr acceler edward deliv top line
mse organ growth line mse tavr deliv
organ growth vs mse us procedur volum
repres pt momentum acceler further convict low-
risk expans ou volum high-teen y/i global tavr notch
pt momentum acceler follow pt tmtt came
mse consensu primarili result known
voluntari pascal recal note guidanc remain unchang
ep miss mse primarili result
pronounc sg invest activ offset lower tax rate look
compani rais low end top line guidanc see exhibit
discuss guidanc detail
low-risk expans play us tavr expans track ahead
volum y/i deliv momentum acceler third quarter
row pt pt pt respect edward competit share
posit remain rel stabl global guidanc continu
reflect share pressur result competitor launch
manag suggest ex us procedur growth high teen vs model
impli low teen yet squar differ manag
point high end decemb tavr guidanc found
two dynam encourag relat surgic structur heart
guidanc maintain despit tavr out-performance suggest better
inspiri perform market expans tavr expans
low-risk patient reflect adopt across risk curv element
impli wider funnel patient potenti longer durabl tail
tavr expans elong tavr expans may help eas concern
deceler less robust catalyst pipelin discuss
rais guidanc earli edward increas top line guidanc vs
mse circl high end organ growth rang vs
mse guidanc top line ep also
mse respect exhibit full list guidanc
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
item edward rais mid point corpor guidanc roughli
equat rais tavr guidanc els equal drive
ep upsid midpoint align guidanc rais
path concern around deceler procedur
growth follow anniversari acceler sale suggest
base go higher edward may will drive
earn upsid pascal potenti us launch earli tavr
readout bigger catalyst year versu manag commentari
organ growth driven continu expans alarm
expect tmtt busi improv follow pascal field recal
reiter guidanc leav us comfort continu anticip
modest headwind on-going patent litig episod abbott
uk verdict come germani hear march juli
us hear schedul may outcom germani
pronounc impact given pascal revenu exposur germani
impact perman injunct could chip away bp
corpor growth meaning impact sentiment said
given short patent life left mitralclip dont see dynam
meaning edward npv pipelin across portfolio continu
advanc sapien pivot enrol begin control
arm yet disclos harpoon launch immin follow eu
approv pascal clasp iid target full enrol ye
low-risk march reiter overweight low-risk expans pascal
roll-out continu underpin thesi addit low-risk inflect
drive tavr momentum see tavr savr gain equal foot
funnel widen patient across risk spectrum come view
creat longer tail tavr expans increas edward market access
reinforc growth progress reiter ow
maintain pt
high end
high end
tavr market expans continu low risk mitral catalyst
tavr market expans continu low risk mitral catalyst
tavr market reach global see gradual
expans low risk popul follow low-risk data
complement growth rate higher risk us eu popul
ew share declin time remain market leader
coapt result mitral path forward key edward trial
timelin launch need addit clariti oper leverag
acceler long-term margin reach
edward maintain share market share tavr market grow
bn tavr increasingli becom therapi choic even
low risk patient drive penetr global mitral innov
progress faster expect price declin lower expect
base case ep support dcf base analysi
base case ep support dcf base analysi
tavr market reach global see gradual expans
low risk popul follow low-risk data complement
growth rate higher risk us eu popul ew share declin
time remain market leader coapt result mitral path
forward key edward trial timelin launch need addit clariti
oper leverag acceler long-term margin reach
risk prove bridg far valv durabl remain outstand issu
younger patient still tavr market grow billion
long-term potenti market expans
lower risk patient remain
underappreci drive
out-performance time see market
expans billion said
near term intermedi risk penetr
durabl reflect growth inflect
continu see increment
ebitda margin tavr sale
drive long-term corpor ebit margin
high near term reinvest like
mitral visibl remain low faster
develop could support bull case
project robust mitral opportun
potenti market size aortic
market discount heavili base
case reflect signific uncertainti
futur market
penetr tavr lower risk
popul critic near term
increas visibl structur heart
portfolio key durabl long term growth
risk achiev price
robust commerci traction boston
abbott/st jude long term
potenti pipelin develop failur
mitral space
us european reimburs pressur
price time
limit low risk intermedi risk traction sapien share slip
traction acceler competit boston off-set
peer
million except ep
sale
sale
sale
sale
equival
prepaid expens ca
net chang work capit
oper
invest intang asset
invest unconsolid affili
proce asset disposit
proce sale busi
proce note receiv
invest
proce issuanc long-term debt
payment long-term debt
proce issuanc short-term debt
payment short-term debt
chang equiti net tax benefit
payment relat ar securit net
financ
effect currenc exchang
